natgillin/translations-raw huggingface dataset:
Common side effects (likely to occur in more than 1 out of 100 persons and less than 1 out of 10 persons): changes in number of blood cells (red cells, white cells and platelets), reduced appetite, depression, irritability, headache, fainting, fluid retention (swelling), taste disturbances, pain in the abdomen, vomiting, nausea, constipation, skin odour, rash, abnormal kidney function, weight gain and altered laboratory test values.
Pogosti neželeni učinki (pojav teh je možen pri več kot 1 od 100 oseb in pri manj kot 1 od 10 oseb): nenormalne koncentracije krvničk (rdečih krvničk, belih krvničk, krvnih ploščic), zmanjšan tek, depresivnost, preobčutljivost, glavobol in omedlevica, zastoj tekočin (otekanje), motnje okušanja, bolečine v trebuhu, bruhanje, slabost s siljenjem na bruhanje (navzeja), zapeka, neprijeten telesni vonj, izpuščaj, nenormalno delovanje ledvic, zvišana telesna masa, nenormalni rezultati laboratorijskih preiskav.
Uncommon side effects (likely to occur in more than 1 out of 1,000 persons and less than 1 out of 100 persons): deficiency in red blood cells due to bone marrow depression, bruising, altered heart rhythm, rectal bleeding, stomach irritation, stomach ulcer, inflammation of the pancreas.
Občasni neželeni učinki (pojav teh je možen pri več kot 1 od 1. 000 oseb in pri manj kot 1 od 100 oseb): zmanjšanje števila rdečih krvničk zaradi zmanjšane dejavnosti kostnega mozga, modrice, spremenjen srčni ritem, krvavitev iz danke, razdražen želodec, želodčna razjeda, vnetje trebušne slinavke.
HOW TO STORE AMMONAPS
SHRANJEVANJE ZDRAVILA AMMONAPS
Do not use AMMONAPS after the expiry date which is stated on the carton and the bottle label after “ EXP”.
Zdravila AMMONAPS ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki na plastenki poleg oznake “ EXP ”.
What AMMONAPS contains
Kaj vsebuje zdravilo AMMONAPS
- The active substance is sodium phenylbutyrate.
- Zdravilna učinkovina je natrijev fenilbutirat.
Each tablet of AMMONAPS contains 500 mg
Vsaka tableta AMMONAPS vsebuje 500 mg
of sodium phenylbutyrate.
natrijevega fenilbutirata.
- The other ingredients are microcrystalline cellulose, magnesium stearate and colloidal
- Pomožne snovi so mikrokristalna celuloza, magnezijev stearat in brezvoden koloidni silicijev
anhydrous silica.
dioksid.
27 What AMMONAPS looks like and contents of the pack AMMONAPS tablets are off-white, oval and embossed with “ UCY 500”.
Izgled zdravila AMMONAPS in vsebina pakiranja Tablete AMMONAPS so sivo bele, ovalne in imajo vrezan napis “ UCY 500 ”.
The tablets are packaged in plastic bottles with child-resistant caps.
Tablete so pakirane v plastenke z otrokom varno zaporko.
Marketing Authorisation Holder Swedish Orphan International AB Drottninggatan 98 SE-111 60 Stockholm Sweden
Imetnik dovoljenja za promet z zdravilom Swedish Orphan International AB Drottninggatan 98 SE- 111 60 Stockholm Švedska
Manufacturer Bioglan AB Borrgatan 31 SE-211 24 Malmö Sweden
Izdelovalec Bioglan AB Borrgatan 31 SE- 211 24 Malmö Švedska
28 PACKAGE LEAFLET:
28 NAVODILO ZA UPORABO
AMMONAPS 940 mg/ g granules sodium phenylbutyrate
AMMONAPS 940 mg/ g zrnca natrijev fenilbutirat
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
- Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen
If you require laboratory tests, it is important to remind your doctor that you take AMMONAPS, since sodium phenylbutyrate may influence certain laboratory test results.
Če boste morali opraviti laboratorijske preiskave, je pomembno, da opomnite svojega zdravnika, da jemljete zdravilo AMMONAPS, ker lahko natrijev fenilbutirat vpliva na rezultate nekaterih laboratorijskih preiskav.
29 Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
29 Jemanje drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Important information about some of the ingredients of AMMONAPS One small spoon of AMMONAPS granules contains 118 mg of sodium.
Pomembne informacije o nekaterih sestavinah zdravila AMMONAPS Majhna žlička zrnc zdravila AMMONAPS vsebuje 118 mg natrija.
One medium sized spoon of AMMONAPS granules contains 360 mg of sodium.
Srednja žlička zrnc zdravila AMMONAPS vsebuje 360 mg natrija.
One large spoon of AMMONAPS granules contains 1066 mg of sodium.
Velika žlička zrnc zdravila AMMONAPS vsebuje 1066 mg natrija.
You should take AMMONAPS in equally divided doses by mouth, through a gastrostomy (tube through the abdomen to the stomach) or through a nasogastric tube (tube through the nose to the stomach).
AMMONAPS morate jemati v enakomerno razdeljenih odmerkih skozi usta ali gastrostomo (cevko skozi trebuh v želodec) ali nazogastrično cevko (cevko skozi nos v želodec).
In small children this can be 4 to 6 times per day.
Pri majhnih otrocih je to lahko 4 do 6- krat dnevno.
To measure the dose: • Shake the bottle lightly before opening • Use the correct spoon:
Postopek za odmerjanje zdravila AMMONAPS: • Pred odmerjanjem rahlo pretresite plastenko. • Izberite pravilno merilno žličko:
0.95 g = small spoon, 2.9 g = medium sized spoon and 8.6 g = large spoon • Take a heaped spoonful of granules out of the bottle • Pass a flat surface, e. g. the back of a knife blade, over the top of the spoon to remove the excess of granules • The granules left in the spoon are one spoonful • Take the correct number of spoonful granules from the bottle
0, 95 g = majhna žlička; 2, 9 g = srednja žlička in 8, 6 g = velika žlička. • Iz plastenke vzemite zvrhano merilno žličko zrnc zdravila. • S plosko površino (npr. rezilom noža) potegnite po žlički, da odstranite odvečno količino zrnc. • Zrnca, ki ostanejo v žlički so ena merica. • Iz plastenke vzemite pravilno število meric zrnc.
30 When taken by mouth:
30 Bolniki z gastrostomo ali nazogastrično cevko:
Mix the measured dose with solid foods (such as mashed potatoes or apple sauce) or liquid foods (such as water, apple juice, orange juice or protein-free infant formulas) and take it immediately after mixing.
Zmešajte zrnca z vodo, dokler se ne raztopijo (če raztopino premešate se zrnca hitreje raztopijo).
Patients with a gastrostomy or nasogastric tube:
Ko se zrnca raztopijo v vodi, nastane mlečno bela tekočina.
Take the solution immediately after mixing.
Raztopino uporabite takoj po pripravi
If you take more AMMONAPS than you should Patients who have taken very high doses of AMMONAPS experienced sleepiness, tiredness, light- headedness and less frequently confusion, headache, taste disturbances, decrease in hearing, disorientation, impaired memory and worsening of existing neurological conditions.
Če ste uporabili večji odmerek zdravila AMMONAPS, kot bi smeli Pri bolnikih, ki so vzeli zelo velike odmerke zdravila AMMONAPS, se je pojavila zaspanost, utrujenost, vrtoglavost, redkeje pa zmedenost, glavobol, motnje okušanja, naglušnost, dezorientiranost, spominske motnje in poslabšanje obstoječih nevroloških stanj.
If you forget to take AMMONAPS You should take a dose as soon as possible with your next meal.
Če ste pozabili vzeti zdravilo AMMONAPS Vzemite odmerek takoj, ko je možno, z naslednjim obrokom.
AMMONAPS granules can be removed from the refrigerator for one single period of maximum 3 months and stored at a temperature not above 25°C, after which the product must be discarded.
31 V času roka uporabnosti lahko zdravilo AMMONAPS zrnca shranite izven hladilnika za enkratno obdobje 3 mesecev pri temperaturi do 25 °C, zatem morate zdravilo zavreči.
Do not forget to mark the date on the bottle, when removed from the refrigerator.
Ne pozabite označiti plastenke z datumom, ko jo prenesete iz hladilnika.
1 g of AMMONAPS granules contains 940 mg
1 g zdravila AMMONAPS zrnca vsebuje 940 mg
- The other ingredients are calcium stearate and colloidal anhydrous silica.
- Pomožne snovi sta kalcijev stearat in brezvoden koloidni silicijev dioksid.
What AMMONAPS looks like and contents of the pack AMMONAPS granules are off-white.
Izgled zdravila AMMONAPS in vsebina pakiranja Zrnca AMMONAPS so sivo bela.
The granules are packaged in plastic bottles with child-resistant caps.
Zrnca so pakirana v plastenke z otrokom varno zaporko.
Each bottle contains 266 g or 532 g of granules.
Vsaka plastenka vsebuje 266 g ali 532 g zrnc.
Three spoons (one small, one medium and one large) are included to measure your daily dose.
Priložene so tri merilne žličke (ena majhna, ena srednja in ena velika), s katerimi odmerite svoj dnevni odmerek.
Angiox is a white powder that is made up into a solution for injection or infusion (drip into a vein).
Zdravilo Angiox je bel prašek za pripravo raztopine za injiciranje ali infundiranje (kapalna infuzija v veno).
It contains the active substance bivalirudin.
Zdravilo Angiox vsebuje zdravilno učinkovino bivalirudin.
Angiox is used to treat adults with ‘ acute coronary syndromes’ (ACS, reduced blood flow to the heart), such as unstable angina (a type of chest pain that varies in severity) or myocardial infarction (heart attack) without ‘ ST segment elevation’ (an abnormal reading on the electrocardiogram or ECG).
Angiox se uporablja za zdravljenje odraslih ljudi z „ akutnim koronarnim sindromom “ (manjši pretok krvi do srca), kot sta nestabilna angina pektoris (vrsta bolečine v prsih, katere jakost se spreminja) ali miokardni infarkt (srčni napad) brez „ dviga spojnice ST “ (nenormalen izpis na elektrokardiogramu ali EKG- ju).
It is used together with aspirin and clopidogrel (medicines that help to prevent blood clots) in patients who are about to undergo treatment for their ACS, such as using medicines, undergoing angioplasty or having a heart bypass operation.
Uporablja se skupaj z aspirinom in klopidogrelom (zdravili, ki preprečujeta krvne strdke) pri bolnikih, ki se bodo začeli zdraviti zaradi akutnega koronarnega sindroma, in sicer z jemanjem zdravil, izvedbo angioplastike ali operacijo srčnega obvoda.
Angioplasty or ‘ percutaneous coronary intervention’ (PCI) is an operation to unblock the heart’ s blood vessels.
Angioplastika ali „ perkutana koronarna intervencija “ (PCI) je kirurški postopek za odpravljanje blokad v srčnih krvnih žilah.
Angiox is also used to prevent blood clots in patients who are going to have PCI.
Zdravilo Angiox se uporablja tudi za preprečevanje krvnih strdkov pri bolnikih, ki čakajo na perkutano koronarno intervencijo.
Angiox is intended to be given intravenously (into a vein).
Zdravilo Angiox je namenjeno intravenski uporabi (dajanju v žilo).
It should be given by a doctor who has experience in the emergency care of patients with heart problems or in carrying out procedures on the heart.
Daje naj ga zdravnik, ki ima izkušnje z nujno oskrbo bolnikov z obolenji srca ali izvedbo posegov na srcu.
The dose of Angiox and duration of treatment depend on why it is being used.
Odmerek zdravila Angiox in trajanje zdravljenja sta odvisna od tega, zakaj se zdravilo uporablja.
The first dose is given by injection, and is followed immediately by an infusion.
Prvi odmerek se injicira, temu pa takoj sledi sledi infundiranje.
For ACS, the duration of the infusion depends on how the ACS is to be treated: it can last for a maximum of 72 hours in patients to be treated with medicines.
Pri akutnem koronarnem sindromu je trajanje infudiranja odvisno od tega, kako se bo akutni koronarni sindrom zdravil: pri bolnikih, ki se bodo zdravili z zdravili, lahko traja največ 72 ur.
When used to prevent blood clots in patients undergoing PCI, a higher dose of Angiox is used, and the infusion may be continued for up to four hours after the procedure.
Kadar se uporabi za preprečevanje krvnih strdkov pri bolnikih, ki prestajajo perkutano koronarno intervencijo, se uporabi večji odmerek zdravila Angiox, z infundiranjem pa se lahko nadaljuje še največ štiri ure po izvedenem posegu.
The infusion doses need to be reduced in patients with kidney problems who are undergoing PCI.
Pri bolnikih z ledvičnimi težavami, ki prestajajo perkutano koronarno intervencijo, morajo biti odmerki infuzije nižji.
Angiox should not be used in patients with severe kidney problems.
Zdravila Angiox se ne sme uporabljati pri bolnikih s hudimi ledvičnimi težavami.
Angiox is an anticoagulant: it prevents the blood from coagulating (clotting).
Zdravilo Angiox je antikoagulant – preprečuje koagulacijo (strjevanje) krvi.
Thrombin is 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Bivalirudin, zdravilna učinkovina v zdravilu Angiox, je sintetična snov, pridobljena iz hirudina, antikoagulacijske snovi, ki jo proizvajajo 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non-commercial or commercial purposes, provided the EMEA is acknowledged central to the processes involved in blood clotting.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non- commercial or commercial purposes, provided the EMEA is acknowledged. pijavke.
By using Angiox during ACS or PCI, the risk of a blood clot forming is greatly reduced.
Le- ta zlasti zavira delovanje trombina, ene izmed snovi, ki sodelujejo v procesu strjevanja krvi.
This can help the flow of blood to the heart to be maintained in patients with angina or who are having a heart attack and can improve the effectiveness of PCI.
Z uporabo zdravila Angiox pri akutnem koronarnem sindromu ali med postopkom PCI se tveganje za nastanek krvnega strdka močno zmanjša.
Angiox has been studied in over 20,000 patients.
Zdravilo Angiox so preučevali pri 20. 000 bolnikih.
For the treatment of ACS, the main study involved almost 14,000 patients and compared the effectiveness of Angiox, taken alone or with a glycoprotein IIb/ IIIa inhibitor (GPI, another type of medicine that helps to prevent blood clots), with the standard treatment combination of heparin (another anticoagulant) and a GPI.
V glavni študiji za zdravljenje akutnega koronarnega sindroma, v katero je bilo vključenih skoraj 14. 000 bolnikov, se je učinkovitost zdravila Angiox, ki se je dajalo samostojno ali v povezavi z zaviralcem glikoproteina IIb/ IIIa (druga vrsta zdravila, ki pomaga preprečevati krvne strdke) primerjala z običajnim kombiniranim zdravljenjem s heparinom (drugim antikoagulantom) in zaviralcem glikoproteina IIb/ IIIa.
All of the patients also received aspirin, with or without clopidogrel.
Vsi bolniki so prejemali tudi aspirin, s klopidogrelom ali brez njega.
The effectiveness of Angiox in PCI has been studied in over 6,000 patients.
Učinkovitost zdravila Angiox v postopku PCI je bila dokazana v študijah, v katerih je sodelovalo več kot 6. 000 bolnikov.
Angiox was compared with heparin.
Zdravilo Angiox so primerjali s heparinom.
During the PCI, patients often had a stent inserted (a short tube that remains in the artery to stop it closing), and they also received other medicines that help to prevent blood clots, such as abciximab and aspirin.
Med postopkom PCI so bolnikom pogosto vstavili stent (kratko cevko, ki ostane v arteriji in preprečuje zaprtje arterije), dobili pa so tudi druga zdravila proti strjevanju krvi, kot sta abciksimab in aspirin.
For all of the studies, there were four main measures: rates of death, heart attack, urgent revascularisation (restoring blood flow to the heart) and major bleeding.
Pri vseh študijah so bili uporabljeni 4 glavni kriteriji: smrtnost, srčni napad, nujna revaskularizacija (ponovna vzpostavitev krvnega pretoka do srca) in večja krvavitev.
What benefit has Angiox shown during the studies?
Kakšne koristi je zdravilo Angiox izkazalo med raziskavami?
Angiox was as effective as the comparator treatments.
Zdravilo Angiox je bilo enako učinkovito kot zdravljenje s primerjalnimi učinkovinami.
When used to treat ACS, Angiox, taken with or without a GPI, was as effective as the standard treatment in preventing the overall number of new events (deaths, heart attacks or revascularisations) after 30 days and after a year.
Pri zdravljenju akutnega koronarnega sindroma je bilo zdravilo Angiox, ki se je vzelo z zaviralcem glikoproteina IIb/ IIIa ali brez njega, po 30 dneh in enem letu enako učinkovito kot običajno zdravljenje pri preprečevanju skupnega števila novih dogodkov (smrti, srčnih napadov ali revaskularizacij).
Angiox was most effective in patients who also took aspirin and clopidogrel.
Zdravilo Angiox je bilo najučinkovitejše pri bolnikih, ki so jemali tudi aspirin in klopidogrel.
Patients receiving Angiox without GPI also had a lower rate of bleeding after 30 days and after a year.
Bolniki, ki so zdravilo Angiox prejemali brez zaviralca glikoproteina IIb/ IIIa, so tudi imeli nižjo stopnjo krvavitve po 30 dneh in enem letu.
In patients undergoing PCI, Angiox was as effective as heparin in all measures, except major bleeding, for which it was significantly better than heparin.
Pri bolnikih, ki so prestajali postopek PCI, je bilo zdravilo Angiox enako učinkovito kot heparin z vidika vseh kriterijev, razen z vidika večje krvavitve, kjer se je izkazalo kot znatno boljše zdravilo kot heparin.
For the full list of all side effects reported with Angiox, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Angiox, glejte Navodilo za uporabo.
Angiox should not be used in people who may be hypersensitive (allergic) to bivalirudin, other hirudins, or any of the other ingredients.
Zdravila Angiox ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) bivalirudin, druge hirudine ali katero koli drugo sestavino zdravila Angiox.
It should also not be used in patients who have had recent bleeding, who have severe high blood pressure or severe kidney problems, or a heart infection.
Prav tako ga ne smejo uporabljati osebe, ki so nedavno imele krvavitev, ter osebe z resnimi težavami zaradi povišanega krvnega tlaka ali hudo ledvično okvaro ali okužbo srca.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Angiox is an acceptable substitute for heparin in the treatment of ACS and during PCI.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da je zdravilo Angiox sprejemljiv nadomestek za heparin pri zdravljenju akutnega koronarnega sindroma ali med postopkom PCI.
The Committee concluded that Angiox’ s benefits are greater than its risks for the treatment of adult patients with ACS planned for urgent or early intervention, with aspirin and clopidogrel, and as an anticoagulant in patients undergoing PCI.
Odbor je odločil, da so koristi zdravila Angiox večje od z njim povezanih tveganj za zdravljenje odraslih z akutnim koronarnim sindromom, za katere je načrtovana nujna ali predčasna intervencija, v kombinaciji z aspirinom in klopidogrelom ter kot antikoagulant pri bolnikih, ki so podvrženi postopku perkutane koronarne intervencije (PCI).
The Committee recommended that Angiox be given marketing authorisation.
Zato je priporočil, da se za zdravilo Angiox podeli dovoljenje za promet z zdravilom.
Other information about Angiox:
Druge informacije o zdravilu Angiox:
The European Commission granted a marketing authorisation valid throughout the European Union for Angiox to The Medicines Company UK Ltd on 20 September 2004.
Evropska komisija je dovoljenje za promet z zdravilom Angiox, veljavno po vsej Evropski uniji, odobrila družbi The Medicines Company UK Ltd dne 20. septembra 2004.
The full EPAR for Angiox is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Angiox je na voljo tukaj.
This summary was last updated in 01-2008.
Povzetek je bil nazadnje posodobljen 01- 2008.
Angiox 250 mg powder for concentrate for solution for injection or infusion
Angiox 250 mg prašek za koncentrat za raztopino za injiciranje ali infundiranje.
Powder for concentrate for solution for injection or infusion.
Prašek za koncentrat za raztopino za injiciranje ali infundiranje.
White to off-white lyophilised powder
Bel ali sivo bel liofiliziran prašek.
For the treatment of adult patients with acute coronary syndromes (unstable angina/ non-ST segment elevation myocardial infarction (UA/ NSTEMI)) planned for urgent or early intervention.
Za zdravljenje bolnikov z akutnim koronarnim sindromom (nestabilna angina (UA) / infarkt miokarda brez elevacije ST- segmenta (NSTEMI)), načrtovan za urgentno ali zgodnjo intervencijo.
Angiox should be administered with aspirin and clopidogrel.
Zdravilo Angiox je treba dajati z acetilsalicilno kislino in klopidogrelom.
An anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Antikoagulant za bolnike pri katerih se bo izvedla perkutana koronarna intervencija (PCI – » percutaneous coronary intervention «).
Angiox is intended for intravenous (IV) use.
Zdravilo Angiox je namenjeno intravenski (i. v.) uporabi.
Adults/ Elderly
Odrasli/ starejši
Acute coronary syndromes (ACS)
Akutni koronarni sindrom (AKS)
The recommended starting dose of Angiox for patients with ACS is an intravenous bolus of 0.1 mg/ kg followed by an infusion of 0.25 mg/ kg/ h.
Priporočeni odmerek zdravila Angiox pri bolnikih z AKS je 0, 1 mg/ kg kot intravenski bolus, ki mu sledi infundiranje 0, 25 mg/ kg/ h.
Patients who are to be medically managed may continue the infusion of 0.25 mg/ kg/ h for up to 72 hours.
Pri bolnikih, ki bodo v nadaljnji zdravstveni obdelavi, lahko nadaljujete z infuzijo 0, 25 mg/ kg/ h, do 72 ur.
If the patient proceeds to PCI, an additional bolus of 0.5 mg/ kg should be administered and the infusion increased to 1.75 mg/ kg/ h for the duration of the procedure.
Če je bolnik napoten na PCI, je treba dati dodatni bolus 0, 5 mg/ kg, hitrost infundiranja pa čez celoten čas postopka povečati na 1, 75 mg/ kg/ h.
Following PCI, the reduced infusion dose of 0.25 mg/ kg/ h may be resumed for 4 to 12 hours as clinically necessary.
Po PCI lahko nadaljujete z dajanjem zmanjšanega infuzijskega odmerka 0, 25 mg/ kg/ h¸ v trajanju 4 do 12 ur, v skladu s kliničnimi potrebami.
For patients who proceed to coronary artery bypass graft (CABG) surgery off pump, the IV infusion of bivalirudin should be continued until the time of surgery.
Pri bolnikih, ki bodo deležni kirurškega postopka koronarne arterijske premostitve (CABG – » coronary artery bypass graft «) brez uporabe črpalke, je treba uporabljati intravensko infuzijo bivalirudina do začetka kirurškega posega.
Just prior to surgery, a 0.5mg/ kg bolus dose should be administered followed by a 1.75mg/ kg/ h infusion for the duration of the surgery.
Tik pred izvedbo kirurškega posega je treba injicirati 0, 5 mg/ kg bolusni odmerek, čemur sledi infundiranje 1, 75 mg/ kg/ h, ki poteka med posegom.
2 For patients who proceed to CABG surgery on pump, the IV infusion of bivalirudin should be continued until 1 hour prior to surgery after which the infusion should be discontinued and the patient treated with unfractionated heparin.
2 Pri bolnikih, ki bodo deležni kirurškega postopka CABG ob uporabi črpalke, morate z intravensko infuzijo bivalirudina nadaljevati do 1 ure pred operacijo, po postopku pa infuzijo prekiniti in bolnika zdraviti z nefrakcioniranim heparinom.
The recommended dose of Angiox for patients undergoing PCI is an intravenous bolus of 0.75 mg/ kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/ kg body weight/ hour for at least the duration of the procedure.
Priporočeni odmerek zdravila Angiox pri bolnikih, pri katerih se bo izvedla PCI, je intravenski bolus 0, 75 mg/ kg telesne mase, ki mu takoj sledi intravenska infuzija s hitrostjo 1, 75 mg/ kg telesne mase/ uro vsaj v času trajanja postopka.
The infusion may be continued for up to 4 hours post-PCI as clinically warranted.
S klinično gotovostjo lahko z infuzijo nadaljujete še največ 4 ure po PCI.